文献类型：期刊文献

中文题名：内消瘰疬丸对乳腺增生患者乳腺超声指标及生殖激素水平的影响

英文题名：Effects of Neixiao Luoli Wan on breast ultrasound indexes and reproductive hormone levels in patients with breast hyperplasia

作者：王嘉图[1];赵丽[1];尹世淩[1];付兆媛[1];赵雪灵[1];毛宇宏[2]

第一作者：王嘉图

机构：[1]甘肃中医药大学附属医院超声科,甘肃兰州730000;[2]甘肃中医药大学针灸推拿学院,甘肃兰州730000

第一机构：甘肃中医药大学第二附属医院

年份：2022

卷号：21

期号：14

起止页码：1541

中文期刊名：临床和实验医学杂志

外文期刊名：Journal of Clinical and Experimental Medicine

收录：CSTPCD

基金：甘肃省自然科学基金(编号:20JR5RA166)。

语种：中文

中文关键词：乳腺增生;超声;内消瘰疬丸;生殖激素

外文关键词：Mammary hyperplasia;Ultrasound;Neixiao Luoli Wan;Reproductive hormone

摘要：目的探讨内消瘰疬丸对乳腺增生患者乳腺超声指标及生殖激素水平的影响,并通过超声分级评估法评价该药物对乳腺增生症的临床疗效。方法采用前瞻性研究,选取2020年7月至2021年12月甘肃中医药大学附属医院共收治乳腺增生女性患者122例作为研究对象。按照随机数字表法分为两组,各61例,其中观察组给予内消瘰疬丸治疗,对照组给予百消丹治疗。比较两组临床疗效、乳腺超声检查指标和生殖激素水平。同时,根据乳腺增生症状的4个超声表现,采用分级评估法评价药物对乳腺增生症治疗的效果。结果观察组治疗有效率为93.44%,显著性高于对照组(80.32%),差异有统计学意义(P<0.05)。治疗后,观察组乳腺腺体层厚度、输乳管内径、囊肿和低回声区直径分别为(8.81±2.61)、(1.54±0.39)、(1.60±0.52)、(14.39±3.32)mm,均显著低于对照组[(9.89±2.46)、(1.74±0.43)、(2.13±0.53)、(17.14±2.91)mm],差异均有统计学意义(P<0.05)。与治疗前相比,两组治疗后0~Ⅰ级患者均显著增加,而Ⅱ~Ⅲ级患者则显著减少,差异均有统计学意义(P<0.05);但两组治疗前后分级结果差异无统计学意义(P>0.05)。治疗后,两组患者的血清雌二醇、催乳素均显著低于治疗前,而血清孕酮显著高于治疗前,差异均有统计学意义(P<0.05);治疗后,观察组的血清雌二醇和催乳素(86.00±33.80)pg/mL、(299.74±54.63)uIU/mL,显著低于对照组[(91.67±39.34)pg/mL、(320.48±71.58)uIU/mL],而孕酮为(5.27±4.28)ng/L,显著高于对照组[(4.33±3.35)ng/L],差异均有统计学意义(P<0.05)。结论采用超声分级评估法能客观、准确地评价内消瘰疬丸对乳腺增生的治疗效果,为临床诊断乳腺增生症提供一种辅助方法。
Objective To explore the clinical effects of Neixiao Luoli Wan on indicators of mammary hyperplasia and serum reproductive hormone in patients,and evaluate the clinical its efficacy on mammary hyperplasia by ultraphonic gradational assessment.Methods A prospective study was used to select 122 female patients with breast hyperplasia who were admitted to the Affiliated Hospital of Gansu University of Traditional Chinese Medicine from July 2020 to December 2021 as the research subjects.According to the random number table method,they were divided into two groups,with 61 cases in each group.The observation group was given Neixiao Luoli Wan,and the control group was given Baixiaodan.The clinical efficacy,mammary ultrasound examination and reproductive hormone levels,including estradiol,progesterone and prolactin,in two groups were recorded and compared.The effect of the drugs on the mammary hyperplasia was further evaluated using a grading assessment method according to the mammary ultrasound examination.Results The effective rate of the observation group was 93.44%,which was significantly higher than that of the control group(80.32%),and the difference was statistically significant(P<0.05).After treatment,the thickness of the breast gland,the inner diameter of mammary duct,the diameters of the lump and the low echo area in the observation groups were(8.81±2.61),(1.54±0.39),(1.60±0.52),(14.39±3.32)mm,which were significantly lower than that in the control group[(9.89±2.46),(1.74±0.43),(2.13±0.53),(17.14±2.91)mm],and the difference was statistically significant(P<0.05).Compared with before treatment,the number of patients in grades 0-Ⅰin both groups increased significantly after treatment,while the patients in gradesⅡ-Ⅲdecreased significantly(P<0.05);however,there was no significant difference in the grading results between the two groups before and after treatment(P>0.05).After treatment,serum estradiol and prolactin of the two groups were significantly lower than before treatment,while serum progesterone was significantly higher than before treatment(P<0.05).After treatment,the serum estradiol and prolactin in the observation group were(86.00±33.80)pg/mL,(299.74±54.63)uIU/mL,which were significantly lower than the control group[(91.67±39.34)pg/mL,(320.48±71.58)uIU/mL],the progesterone was(5.27±4.28)ng/L,which was significantly higher than that of the control group[(4.33±3.35)ng/L],and the differences were statistically significant(P<0.05).Conclusion The clinic effects of the Neixiao Luoli Wan were objectively and accurately evaluated with the ultraphonic gradational assessment method,and therefore providing an auxiliary method for the clinical diagnosis of mammary hyperplasia.